Moderna Inc.’s (NASDAQ: MRNA) Vaccine Effective Against Delta Variant Than Pfizer Inc.’s (NYSE: PFE), Study Shows

A study by Mayo Clinic has shown that the risk of someone vaccinated with the Moderna Inc. (NASDAQ: MRNA) vaccine getting infected with the delta variant is lower compared to someone who received the Pfizer Inc. (NYSE: PFE) vaccine. 

Moderna vaccine offers more protection than Pfizer vaccine 

Results of the study awaiting review established that, in Florida were coronavirus cases were at all-time high in July and the delta variant was prevalent, the risk of breakthrough infection was 60% lower for people who received Moderna vaccine compared to Pfizer vaccine.  A similar study in Minesota showed that Moderna vaccine was 76% effective against SARS-CoV-2 while Pfzer vaccine was 42% effective. 

An Abstract of the study indicated, “Comparing rates of infection between matched individuals fully vaccinated with mRNA-1273 versus BNT162b2 across Mayo Clinic Health System sites in multiple states (Minnesota, Wisconsin, Arizona, Florida, and Iowa), mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2.”

Interestingly, the researchers established that both vaccines were effective in protecting against severe disease and the difference is all about whether individuals get infected in the first place. According to the CDC the infection risk is 8X high for unvaccinated individuals than vaccinated with the hospitalization risk or death being 25x higher. 

Pfizer and BioNTech working in booster vaccine for COVID-19 variants 

Pfizer said that they expect to come up and manufacture a vaccine specific to a variant within 100 days subject to regulatory approval. In a subsequent statement the company affirmed its vaccine efficacy and committed to create boosters. 

According to a statement from Pfizer and BioNTech the companies have put in place a booster research program seeking to ensure their vaccine continues to offer enhanced protections. Preliminary data regarding a third dose show that a booster dose given after six months of a second dose will trigger neutralization titers against the wild type, Delta, and Beta variants.

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at